chr10-53806693-G-GTCAA
Position:
Variant summary
Our verdict is Uncertain significance. Variant got 4 ACMG points: 4P and 0B. PVS1_ModeratePM2
The NM_001384140.1(PCDH15):c.5108_5109insTTGA(p.Ser1704Ter) variant causes a stop gained, frameshift change. The variant allele was found at a frequency of 0.0000682 in 1,613,728 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Genomes: 𝑓 0.000072 ( 0 hom., cov: 32)
Exomes 𝑓: 0.000068 ( 0 hom. )
Consequence
PCDH15
NM_001384140.1 stop_gained, frameshift
NM_001384140.1 stop_gained, frameshift
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 5.96
Genes affected
PCDH15 (HGNC:14674): (protocadherin related 15) This gene is a member of the cadherin superfamily. Family members encode integral membrane proteins that mediate calcium-dependent cell-cell adhesion. It plays an essential role in maintenance of normal retinal and cochlear function. Mutations in this gene result in hearing loss and Usher Syndrome Type IF (USH1F). Extensive alternative splicing resulting in multiple isoforms has been observed in the mouse ortholog. Similar alternatively spliced transcripts are inferred to occur in human, and additional variants are likely to occur. [provided by RefSeq, Dec 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Uncertain_significance. Variant got 4 ACMG points.
PVS1
Loss of function variant, product does not undergo nonsense mediated mRNA decay. Variant is located in the 3'-most exon, not predicted to undergo nonsense mediated mRNA decay. Fraction of 0.022 CDS is truncated, and there are 1 pathogenic variants in the truncated region.
PM2
Very rare variant in population databases, with high coverage;
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
PCDH15 | NM_001384140.1 | c.5108_5109insTTGA | p.Ser1704Ter | stop_gained, frameshift_variant | 38/38 | ENST00000644397.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
PCDH15 | ENST00000644397.2 | c.5108_5109insTTGA | p.Ser1704Ter | stop_gained, frameshift_variant | 38/38 | NM_001384140.1 |
Frequencies
GnomAD3 genomes AF: 0.0000723 AC: 11AN: 152114Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
11
AN:
152114
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000804 AC: 20AN: 248696Hom.: 0 AF XY: 0.000104 AC XY: 14AN XY: 135132
GnomAD3 exomes
AF:
AC:
20
AN:
248696
Hom.:
AF XY:
AC XY:
14
AN XY:
135132
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000677 AC: 99AN: 1461614Hom.: 0 Cov.: 33 AF XY: 0.0000564 AC XY: 41AN XY: 727090
GnomAD4 exome
AF:
AC:
99
AN:
1461614
Hom.:
Cov.:
33
AF XY:
AC XY:
41
AN XY:
727090
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000723 AC: 11AN: 152114Hom.: 0 Cov.: 32 AF XY: 0.0000942 AC XY: 7AN XY: 74302
GnomAD4 genome
AF:
AC:
11
AN:
152114
Hom.:
Cov.:
32
AF XY:
AC XY:
7
AN XY:
74302
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:3
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | May 07, 2015 | The p.Ser1646X variant in PCDH15 has not been previously reported in individuals with hearing loss, but has been identified in 0.1% (6/8626) of East Asian chrom osomes by the Exome Aggregation Consortium (ExAC, http://exac.broadinstitute.org ). Although this variant has been seen in the general population, its frequency is not high enough to rule out a pathogenic role. This variant is predicted to c ause a frameshift, which introduces a premature termination codon at position 16 46 of an alternatively spliced PCDH15 transcript (NM_001142771.1). This terminat ion codon occurs within the terminal 50 bases of the last exon and is more likel y to escape nonsense mediated decay (NMD) and result in a slightly truncated pro tein. Furthermore, this variant is expected to fall within the cytoplasmic domai n (CD) of PCDH15. Truncating variants in the CD of a different PCDH15 isoform ar e known to occur at high frequency and are therefore less likely to cause diseas e (Perreault-Micale 2014). In summary, the clinical significance of the p.Ser164 6X variant is uncertain. - |
Usher syndrome type 1D;C1836027:Autosomal recessive nonsyndromic hearing loss 23;C1865885:Usher syndrome type 1F Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Oct 01, 2021 | - - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Clinical Genetics Laboratory, Skane University Hospital Lund | Mar 01, 2024 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at